share_log

PainReform | 6-K: Report of foreign private issuer (related to financial reporting)

PainReform | 6-K: Report of foreign private issuer (related to financial reporting)

PainReform | 6-K：外国发行人报告（业绩相关）
美股SEC公告 ·  2024/08/16 04:47

Moomoo AI 已提取核心信息

PainReform reported a net loss of $12.8M for H1 2024, compared to $4.5M in H1 2023, primarily due to increased Phase 3 trial expenses. Research and development costs rose to $11.4M from $2.7M, while general and administrative expenses decreased to $1.5M from $2.0M. The company has enrolled over 200 patients across eight U.S. clinical sites for its PRF-110 post-operative pain treatment trial.The company raised $4.0M through a public offering in April 2024, but management indicates current funds will only support operations through Q4 2024. With cash and cash equivalents of $2.8M as of June 30, 2024, and negative working capital of $1.9M, PainReform faces substantial doubt about its ability to continue as a going concern without additional funding.The Phase 3 clinical trial for PRF-110 continues to progress, with preliminary top-line results expected in Q3 2024. Following completion of the bunionectomy trial, PainReform plans to initiate a second trial for hernia repair operations. The company's development strategy focuses on reformulating established therapeutics using its proprietary extended-release drug-delivery system.
PainReform reported a net loss of $12.8M for H1 2024, compared to $4.5M in H1 2023, primarily due to increased Phase 3 trial expenses. Research and development costs rose to $11.4M from $2.7M, while general and administrative expenses decreased to $1.5M from $2.0M. The company has enrolled over 200 patients across eight U.S. clinical sites for its PRF-110 post-operative pain treatment trial.The company raised $4.0M through a public offering in April 2024, but management indicates current funds will only support operations through Q4 2024. With cash and cash equivalents of $2.8M as of June 30, 2024, and negative working capital of $1.9M, PainReform faces substantial doubt about its ability to continue as a going concern without additional funding.The Phase 3 clinical trial for PRF-110 continues to progress, with preliminary top-line results expected in Q3 2024. Following completion of the bunionectomy trial, PainReform plans to initiate a second trial for hernia repair operations. The company's development strategy focuses on reformulating established therapeutics using its proprietary extended-release drug-delivery system.
PainReform报告2024年上半年净亏损1280万，与2023年上半年450万相比，主要由于第三阶段试验费用增加。研发费用从270万上升至1140万，而一般和管理费用则从200万下降至150万。该公司在美国八个临床地点招募了超过200名患者参与PRF-110术后疼痛治疗试验。该公司在2024年4月通过首次公开募股筹集了400万，但管理层表示，目前的资金仅能支持运营到2024年第四季度。截至2024年6月30日，现金及现金等价物为280万，负流动资金为190万，PainReform面临着其在没有额外资金的情况下能否持续运营的重大疑虑。PRF-110的第三阶段临床试验正在继续进行，初步顶线结果预计在2024年第三季度公布。在完成足部手术试验后，PainReform计划启动第二个腹股沟修复手术的试验。该公司的开发策略专注于使用其专有的缓释药物传递系统对既有疗法进行重新配方。
PainReform报告2024年上半年净亏损1280万，与2023年上半年450万相比，主要由于第三阶段试验费用增加。研发费用从270万上升至1140万，而一般和管理费用则从200万下降至150万。该公司在美国八个临床地点招募了超过200名患者参与PRF-110术后疼痛治疗试验。该公司在2024年4月通过首次公开募股筹集了400万，但管理层表示，目前的资金仅能支持运营到2024年第四季度。截至2024年6月30日，现金及现金等价物为280万，负流动资金为190万，PainReform面临着其在没有额外资金的情况下能否持续运营的重大疑虑。PRF-110的第三阶段临床试验正在继续进行，初步顶线结果预计在2024年第三季度公布。在完成足部手术试验后，PainReform计划启动第二个腹股沟修复手术的试验。该公司的开发策略专注于使用其专有的缓释药物传递系统对既有疗法进行重新配方。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Petros Pharmaceuticals
    PTPI
    -- 0.2930
    坎伯兰药业
    CPIX
    -- 5.150
    OptiNose
    OPTN
    -- 6.000
    Talphera
    TLPH
    -- 0.670
    BioAge Labs
    BIOA
    -- 4.790
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    特斯拉绩后巨震，后市你怎么看？
    特斯拉2024年Q4营收257.1亿美元，同比增长2%，不及预期。Cybercab计划2026年投产，预计车辆业务将于2025年恢复增长。面对特朗普回归，特斯拉股价能否在2025年继续攀升？ 展开
    TSLA财报预告：通过猜测开盘价来获取奖励！